Articles related to LIVER DISEASE

Better Therapeutics’ digital therapeutic app has been recognized with FDA breakthrough device status, showcasing its potential in significantly reducing liver fat in patients with advanced liver disease through cognitive behavioral therapy.

For patients with cirrhosis facing venous thromboembolic events, the choice of anticoagulant—be it DOACs or LMWH—demands careful consideration of their unique hemostatic profile, emphasizing the need for personalized treatment strategies.

In this Phase 3 trial, resmetirom demonstrated a notable capacity to induce NASH resolution and improve liver fibrosis, offering hope for a therapeutic breakthrough in a field with limited treatment options. This study emphasizes the importance of advancing research in liver-directed therapies for NASH.

Recent studies and guidelines are shifting the paradigm in coagulation management for cirrhosis patients undergoing low-risk procedures; discover why traditional markers like INR may not be reliable indicators of bleeding risk.

Explore the latest research illuminating the significant link between sugar-sweetened beverage consumption and liver disease risk in postmenopausal women—evidence that could inform your nutritional guidance to patients.

This phase 1–2 study of gene therapy in Crigler–Najjar syndrome patients offers promising insights into a novel treatment approach. Explore the detailed findings to understand how this therapy could revolutionize the management of this rare and severe condition.